Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036293 | 0.81 | CHRNB2 (0.42) | ARCHRNB2CHRNA4KDM4EMEN1 | |
| SCHEMBL13894319 | 0.79 | HTR2C (0.45) | ARPGRCHRNB2CHRNA4CA1 | |
| SCHEMBL8140136 | 0.79 | DRD2 (0.42) | ARPGRCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL6649781 | 0.78 | AR (0.42) | ARPGRCHRNB2CHRNA4KDM4E | |
| SCHEMBL10229445 | 0.77 | PARP1 (0.37) | ARPGRCHRNB2CHRNA4TDP1 | |
| SCHEMBL6651570 | 0.76 | HTR2C (0.48) | ARPGRCHRNB2CHRNA4MEN1 | |
| SCHEMBL30480890 | 0.76 | HTR2C (0.48) | ARPGRCHRNB2CHRNA4MEN1 | |
| SCHEMBL6650735 | 0.76 | AR (0.44) | ARPGRCHRNB2CHRNA4KDM4E | |
| SCHEMBL17673238 | 0.75 | AR (0.39) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12350365 | 0.73 | HTR2C (0.39) | ARPGRMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-0800519-B1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353640-A1 | NOVEL COUPLING COMPONENTS FOR OXIDATIVE DYES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| WO-2002058652-A1 | NOVEL COUPLING COMPONENTS FOR OXIDATIVE DYES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2002-08-01 | — | — | WO | disclosed |
| EP-1043326-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043325-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | AR 7/4885PGR 29/4885CHRNB2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.